Table I.

Clinical trials involving HbF induction in SCD currently posted in Clinicaltrials.gov.

Trial	NCT identifier	Status	Reported results
Study of decitabine and THU in patients with SCD	NCT01685515	Active, not recruiting	N/A
Gum arabic as a HbF agent in SCA	NCT02467257	Completed	None
Hydroxyurea and erythropoietin to treat SCA	NCT00270478	Completed	None
Study to determine the maximum tolerated dose, safety and effectiveness of pomalidomide for patients with SCD	NCT01522547	Completed	None
Effects of HQK-1001 in patients with SCD	NCT01601340	Completed	None
Decitabine for high-risk SCD	NCT01375608	Completed	4·8% average HbF increase
Effectiveness of arginine as a treatment for SCA	NCT00513617	Completed	None for HbF induction
Fetal haemoglobin induction treatment with metformin	NCT02981329	Recruiting	N/A
Gene transfer for patients with SCD	NCT02186418	Recruiting	N/A
Study of panobinostat in patients with SCD	NCT01245179	Recruiting	N/A
A study to evaluate safety, pharmacokinetic, and biological activity of INCB059872	NCT03132324	Recruiting	N/A
Efficacy of vorinostat to induce HbF in SCD	NCT01000155	Terminated	None; closed for slow accrual

HbF, fetal haemoglobin; N/A, not applicable; NCT, National Clinical Trial registry (https://clinicaltrials.gov/); None, closed or completed without reported results; SCA, sickle cell anaemia; SCD, sickle cell disease; THU, tetrahydrouridine.